1. Andersson T.J. Assessment and treatment of endothelial dysfunction in human // J. Amer. Coll. Cardiology. — 1999. — Vol. 34. — P. 631−638.
2. Banfi C., Mussoni L., Tremoli E. PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms // Minerva Endocrinology. — 2002. — Vol. 27. — P. 181−191.
3. Bell D.M., Johus T.E., Lopez L.M. Endothelial dysfunction: implications for therapy of cardiovascular diseases // Ann. Pharmacotheraphy. — 1998. — Vol. 32. — P. 459−470.
4. Blann A.D. Von Willebrand factor and the endothelium in vascular disease // Brit. J. Biomed. Sci. — 1993. — Vol. 50. — P. 125−129.
5. Blann A.D., Miller J.P., McCollum C.N. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidemia // Atherosclerosis. — 1997. — Vol. 132. — P. 151−156.
6. Britten M., Schuchinger V. The role of endothelial function for ischemic manifestations of coronary atherosclerois // Herz. — 1998. — Vol. 23 (2). — P. 97−105.
7. Cines D.B., Pollak E.S., Buck C.A. et al. Endothelial cell in physiology and in the pathophysiology of vascular disorders // Blood. — 1998. — Vol. 91. — P. 3527−3561.
8. European guidelines in cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (Contituted by representatives of eight societies and by invited experts) // Eur. Heart J. — 2003. — Vol. 24. — P. 1601−1610.
9. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge // Clin. Chem. — 1972. — Vol. 18. — P. 499−502.
10. Juhan Vague I., Alessi M.C. PAI-1 and atherothrombosis // Thromb. Hemost. — 1993. — Vol. 70. — P. 138−153.
11. Lundman P., Eriksson M., Schenck-Gustafsson K. et al. Transient of triglyceridemia decreases vascular reactivity in young healthy men without risk factors for coronary heart disease // Circulation. — 1997. — Vol. 96. — P. 3266−3268.
12. Mannucci P.M. Von Willebrand factor: a marker of endothelial damage // Arterioscler. Thromb. Vasc. Biology. — 1998. — Vol. 18. — P. 135−136.
13. Montalescot G., Philippe F., Ankri A. et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE Trial // Circulation. — 1998. — Vol. 98. — P. 294−299.
14. Panza J.A. Endothelial dysfunction in essential hypertension // Clin. Cardiology. — 1997. — Vol. 20 (Suppl. II). — P. 26−33.
15. Quyyumi A.A. Endothelial functionin health and disease: new insights into the genesis of cardiovascular disease // Amer. J. Med. — 1998. — Vol. 105. — P. 32−39.
16. Sakamoto T., Woodcock-Mitchell J., Marutsuca K. et al. TNF-a and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes // Amer. J. Physiology. — 1999. — Vol. 276 (6), pt. 1. — P. 1391−1397.
17. Van Meijer M., Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis An update // Fibrinolysis. — 1995. — Vol. 9. — P. 263−276.
18. World Health Organization — International Society of Hypertension. Guidelines for the management of hypertension // J. Hypertension. — 1999. — Vol. 17 (2). — P. 151−183.
